TerminatedPhase 4ACTRN12615000333516

Novel approaches to manage glucocorticoid-induced diabetes in hospital inpatients

The effects of liraglutide vs insulin on glycaemic control in inpatients with glucocorticoid-induced diabetes


Sponsor

Alfred Hospital

Enrollment

30 participants

Start Date

May 29, 2014

Study Type

Interventional

Conditions

Summary

High dose steroids can raise blood glucose levels. These can cause infections, prolong hospital stay and even rarely result in death. Little is known about the best way to manage patients with ‘steroid diabetes’. We will study various approaches to manage high glucose levels in patients treated with steroids in hospital. We will use minimally invasive continuous glucose monitoring, a contemporary technology, to compare and evaluate in detail two different treatment schedules. One intervention will combine longer acting and mealtime insulin (conventional regimen), and the other will combine liraglutide, a newer non-insulin injection, together with longer acting insulin. The results of this study will provide important objective pilot data on management of patients with ‘steroid diabetes’ in hospital.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 85 Yearss

Inclusion Criteria2

  • Glucocorticoid-induced or exacerbated diabetes treated with insulin and/or oral glucose-lowering medication(s)
  • Glucose >= 15 mmol/l

Exclusion Criteria9

  • Type 1 diabetes
  • Admission to intensive care
  • Likely to require surgical intervention
  • Likely to be admitted <48 h
  • eGFR <15 ml/min
  • Acute vomiting or history of gastroparesis
  • Known allergy to insulin or GLP-1 agonists
  • Proliferative retinopathy
  • Premenopausal females

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Basal insulin (0.2 U/kg by subcutaneous injection in the morning) + liraglutide (0.6 mg by subcutaneous injection in the morning) for 72 h

Basal insulin (0.2 U/kg by subcutaneous injection in the morning) + liraglutide (0.6 mg by subcutaneous injection in the morning) for 72 h


Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12615000333516